Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, 110016, Shenyang, People's Republic of China.
Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 110016, Shenyang, People's Republic of China.
Nat Commun. 2022 Nov 24;13(1):7228. doi: 10.1038/s41467-022-35033-7.
Sulfur bonds, especially trisulfide bond, have been found to ameliorate the self-assembly stability of homodimeric prodrug nanoassemblies and could trigger the sensitive reduction-responsive release of active drugs. However, the antitumor efficacy of homodimeric prodrug nanoassemblies with single reduction-responsivity may be restricted due to the heterogeneous tumor redox microenvironment. Herein, we replace the middle sulfur atom of trisulfide bond with an oxidizing tellurium atom or selenium atom to construct redox dual-responsive sulfur-tellurium-sulfur and sulfur-selenium-sulfur hybrid chalcogen bonds. The hybrid chalcogen bonds, especially the sulfur-tellurium-sulfur bond, exhibit ultrahigh dual-responsivity to both oxidation and reduction conditions, which could effectively address the heterogeneous tumor microenvironment. Moreover, the hybrid sulfur-tellurium-sulfur bond promotes the self-assembly of homodimeric prodrugs by providing strong intermolecular forces and sufficient steric hindrance. The above advantages of sulfur-tellurium-sulfur bridged homodimeric prodrug nanoassemblies result in the improved antitumor efficacy of docetaxel with satisfactory safety. The exploration of hybrid chalcogen bonds in drug delivery deepened insight into the development of prodrug-based chemotherapy to address tumor redox heterogeneity, thus enriching the design theory of prodrug-based nanomedicines.
硫键,特别是三硫键,已被发现可改善同型二聚体前药纳米组装体的自组装稳定性,并能引发活性药物的敏感还原响应释放。然而,由于肿瘤还原微环境的异质性,具有单一还原响应性的同型二聚体前药纳米组装体的抗肿瘤疗效可能受到限制。在此,我们用氧化的碲原子或硒原子取代三硫键中的中间硫原子,构建氧化还原双响应硫-碲-硫和硫-硒-硫混合硫属键。混合硫属键,特别是硫-碲-硫键,对氧化和还原条件具有超高的双重响应性,可有效解决肿瘤微环境的异质性问题。此外,混合硫-碲-硫键通过提供强大的分子间力和充足的空间位阻促进同型二聚体前药的自组装。硫-碲-硫桥接同型二聚体前药纳米组装体的上述优势提高了多西紫杉醇的抗肿瘤疗效,同时具有令人满意的安全性。药物传递中混合硫属键的探索深化了基于前药的化疗开发以解决肿瘤还原异质性的认识,从而丰富了基于前药的纳米药物的设计理论。